{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:28:06Z","timestamp":1794576486077,"version":"4.9.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2004,8,1]],"date-time":"2004-08-01T00:00:00Z","timestamp":1091318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":5637,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2004,8]]},"DOI":"10.1093\/annonc\/mdh324","type":"journal-article","created":{"date-parts":[[2004,7,26]],"date-time":"2004-07-26T18:40:48Z","timestamp":1090867248000},"page":"1231-1236","source":"Crossref","is-referenced-by-count":26,"title":["Gemtuzumab ozogamicin (MylotargTM) is infrequently associated with sinusoidal obstructive syndrome\/veno-occlusive disease"],"prefix":"10.1016","volume":"15","author":[{"given":"C.","family":"Nabhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Rundhaugen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Jatoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.B.","family":"Riley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Boehlke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.C.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.S.","family":"Tallman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdh324_bb0010","first-page":"1490","article-title":"Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia","volume":"7","author":"Bross","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdh324_bb0015","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.2165\/00003495-200161090-00007","article-title":"Gemtuzumab ozogamicin","volume":"61","author":"McGavin","year":"2001","journal-title":"Drugs"},{"key":"10.1093\/annonc\/mdh324_bb0020","doi-asserted-by":"crossref","first-page":"10506","DOI":"10.1073\/pnas.92.23.10506","article-title":"Calicheamicin-DNA complexes: warhead alignment and saccharide recognition of the minor groove","volume":"92","author":"Ikemoto","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1093\/annonc\/mdh324_bb0025","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1182\/blood.V93.11.3678","article-title":"Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate","volume":"93","author":"Sievers","year":"1999","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh324_bb0030","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1200\/JCO.2001.19.13.3244","article-title":"Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse","volume":"19","author":"Sievers","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh324_bb0035","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/1097-0142(20010715)92:2<406::AID-CNCR1336>3.0.CO;2-U","article-title":"Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation","volume":"92","author":"Giles","year":"2001","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdh324_bb0040","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood.V99.7.2310","article-title":"Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy","volume":"99","author":"Rajvanshi","year":"2002","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh324_bb0045","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1182\/blood.V83.11.3188.3188","article-title":"Molecular cloning of two isoforms of the murine homolog of the myeloid CD33 antigen","volume":"83","author":"Tchilian","year":"1994","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh324_bb0050","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S0140-6736(00)04217-3","article-title":"Repopulation of liver endothelium by bone-marrow-derived cells","volume":"357","author":"Gao","year":"2001","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdh324_bb0055","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1200\/JCO.1990.8.5.813","article-title":"Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia","volume":"8","author":"Cheson","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh324_bb0060","first-page":"20","article-title":"An updated report of the efficacy and safety of gemtuzumab ozogamicin in 188 patients with acute myeloid leukemia in first relapse","volume":"301a","author":"Stadtmauer","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdh324_bb0065","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1182\/blood-2003-01-0255","article-title":"Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation","volume":"102","author":"Wadleigh","year":"2003","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh324_bb0070","first-page":"339a","article-title":"Final results of a multivariate logistic regression analysis to determine factors contributing to the risk of developing hepatic veno-occlusive disease following treatment with gemtuzumab ozogamicin","volume":"100","author":"Erba","year":"2002","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh324_bb0075","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/sj.bmt.1703602","article-title":"Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease","volume":"30","author":"Cohen","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1093\/annonc\/mdh324_bb0080","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/hep.510230326","article-title":"Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: the role of glutathione and relevance to hepatic venoocclusive disease","volume":"23","author":"DeLeve","year":"1996","journal-title":"Hepatology"},{"key":"10.1093\/annonc\/mdh324_bb0085","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1002\/hep.510290615","article-title":"Characterization of a reproducible rat model of hepatic veno-occlusive disease","volume":"29","author":"DeLeve","year":"1999","journal-title":"Hepatology"},{"key":"10.1093\/annonc\/mdh324_bb0090","first-page":"597","article-title":"The human liver after radiation injury. A form of veno-occlusive disease","volume":"48","author":"Reed","year":"1966","journal-title":"Am J Pathol"},{"key":"10.1093\/annonc\/mdh324_bb0095","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/sj.bmt.1703241","article-title":"Gemtuzumab Ozogamicin (Mylotarg) and hepatic veno-occlusive disease: take two acetaminophen","volume":"28","author":"Gordon","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1093\/annonc\/mdh324_bb0100","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/sj.bmt.1703242","article-title":"Development of hepatic veno-occlusive disease after Mylotarg infusion for relapsed acute myeloid leukemia","volume":"28","author":"Tack","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1093\/annonc\/mdh324_bb0105","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s002770000239","article-title":"Hepatic veno-occlusive disease in two patients with relapsed acute myeloid leukemia treated with anti-CD33 calicheamicin (CMA-676) immunoconjugate","volume":"80","author":"Neumeister","year":"2001","journal-title":"Ann Hematol"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdh324_bb0110","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.3816\/CLM.2002.s.007","article-title":"Management of hepatic sinusoidal obstruction syndrome following treatment with gemtuzumab ozogamicin (mylotarg(r))","volume":"2","author":"McDonald","year":"2002","journal-title":"Clin Lymphoma"},{"key":"10.1093\/annonc\/mdh324_bb0115","first-page":"1114","article-title":"Ursodiol does not prevent hepatic venoocclusive disease associated with Mylotarg therapy","volume":"87","author":"Giles","year":"2002","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdh324_bb0120","first-page":"202b","article-title":"Hepatic venoocclusive disease as a complication of Mylotarg The Western Pennsylvania Institute Experience","volume":"98","author":"Lech","year":"2001","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh324_bb0125","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/00007890-198506000-00005","article-title":"The clinical course of 53 patients with venocclusive disease of the liver after marrow transplantation","volume":"39","author":"McDonald","year":"1985","journal-title":"Transplantation"},{"key":"10.1093\/annonc\/mdh324_bb0130","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood.V85.11.3005.bloodjournal85113005","article-title":"The syndrome of hepatic veno-occlusive disease after marrow transplantation","volume":"85","author":"Bearman","year":"1995","journal-title":"Blood"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753420310607?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753420310607?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/15\/8\/1231\/336185\/mdh324.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T22:31:42Z","timestamp":1582237902000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753420310607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2004,8]]}},"alternative-id":["S0923753420310607"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdh324","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2004,8]]}}}